NURS 5432 AQUIFER CASE 14 2026/2027 | Prenatal Care
Complete Solutions | UTA | Pass Guaranteed - A+ Graded
SECTION 1: Case Overview & Patient Presentation (Q1-Q10)
Q1: A 35-year-old female presents to the family medicine clinic reporting a missed
period of approximately 6 weeks. She has a history of regular 28-day menstrual cycles.
Her vital signs are: BP 118/76 mmHg, HR 82 bpm, RR 16/min, Temp 98.4°F, SpO2 99%
on room air. She appears well-nourished and in no acute distress. Which
epidemiological factor most significantly increases her risk for an adverse pregnancy
outcome?
A. Advanced maternal age (≥35 years) [CORRECT]
B. Nulliparity
C. Regular menstrual cycles
D. Normal BMI
Correct Answer: A
Rationale: Advanced maternal age (≥35 years) is a well-established risk factor for
chromosomal abnormalities (e.g., Down syndrome), gestational diabetes, preeclampsia,
and other adverse pregnancy outcomes. Nulliparity is a risk factor but less significant
than advanced age. Regular cycles and normal BMI are actually protective factors, not
risks. (ACOG Practice Bulletin: Prenatal Diagnostic Testing for Genetic Disorders, 2016)
Q2: The patient is a G2P1 with one prior uncomplicated vaginal delivery at age 32. She
reports no history of miscarriage, ectopic pregnancy, or infertility. Her current
medications include a prenatal vitamin started 2 months ago and occasional ibuprofen
for headaches. Which piece of historical information is most critical to obtain next
regarding her obstetric history?
A. Details of her prior delivery including gestational age, birth weight, and any
complications [CORRECT]
,B. The brand of prenatal vitamin she is taking
C. Her exact date of last menstrual period
D. Frequency of ibuprofen use in the past month
Correct Answer: A
Rationale: A detailed obstetric history including prior delivery outcomes, gestational age,
birth weight, mode of delivery, and complications (e.g., gestational diabetes,
preeclampsia, preterm birth) directly informs risk stratification and prenatal care
planning for the current pregnancy. While LMP is important for dating, prior pregnancy
outcomes guide anticipatory guidance and screening. Ibuprofen use should be
addressed but is less critical than obstetric history. (USPSTF: Prenatal Care Guidelines)
Q3: The patient reports her last menstrual period (LMP) was 6 weeks ago. She has been
sexually active with her husband and uses no contraception. She reports breast
tenderness, mild nausea without vomiting, and increased urinary frequency over the
past 2 weeks. Based on these presenting symptoms, what is the most appropriate initial
diagnostic step?
A. Urine beta-hCG testing [CORRECT]
B. Serum quantitative beta-hCG
C. Transvaginal ultrasound
D. Complete blood count
Correct Answer: A
Rationale: Urine beta-hCG testing is the appropriate initial screening test for pregnancy
confirmation in a primary care setting. It is rapid, inexpensive, and highly sensitive.
Serum quantitative beta-hCG is reserved for suspected ectopic pregnancy or monitoring
trends. Transvaginal ultrasound is indicated after pregnancy is confirmed and hCG
levels reach discriminatory zone (~1,500-2,000 mIU/mL). CBC is not indicated at this
stage. (ACOG: Early Pregnancy Loss)
Q4: The patient's urine beta-hCG is positive. She asks about the reliability of home
pregnancy tests versus clinic-based testing. Which statement best explains the clinical
reasoning behind confirming pregnancy with a clinic-based test?
, A. Clinic-based tests use the same monoclonal antibody technology but provide
documentation and may detect lower hCG thresholds [CORRECT]
B. Home pregnancy tests are always less accurate than clinic tests
C. Clinic tests use completely different biochemical principles
D. Home tests are only reliable after 12 weeks gestation
Correct Answer: A
Rationale: Both home and clinic urine pregnancy tests detect beta-hCG using
monoclonal antibody immunoassay technology. Clinic-based tests may have lower
detection thresholds and provide documented results for the medical record, but
accuracy is similar when used correctly. Home tests are reliable as early as the first
missed period. The key difference is documentation and clinical correlation, not
fundamentally different technology. (ACOG: Home Use Tests)
Q5: The patient expresses concern because she is 35 years old and has heard about
increased risks. She asks what specific screening tests are recommended for women of
advanced maternal age. Which response best reflects evidence-based prenatal
screening guidelines?
A. Cell-free DNA testing, detailed anatomy ultrasound, and consideration of diagnostic
testing such as amniocentesis or CVS [CORRECT]
B. Only amniocentesis is recommended for all women over 35
C. No additional screening is needed beyond standard prenatal care
D. Triple screen is the gold standard for women over 35
Correct Answer: A
Rationale: For women ≥35 years, cell-free DNA (cfDNA) testing is recommended as a
first-tier screening option for aneuploidy. A detailed anatomy ultrasound at 18-22 weeks
is standard. Diagnostic testing (amniocentesis or CVS) should be offered and
discussed, particularly if screening is positive or there are additional risk factors.
Amniocentesis is not automatic for all women over 35. The triple/quad screen has been
largely replaced by cfDNA for high-risk populations. (ACOG Practice Bulletin No. 226:
Screening for Fetal Chromosomal Abnormalities)
Complete Solutions | UTA | Pass Guaranteed - A+ Graded
SECTION 1: Case Overview & Patient Presentation (Q1-Q10)
Q1: A 35-year-old female presents to the family medicine clinic reporting a missed
period of approximately 6 weeks. She has a history of regular 28-day menstrual cycles.
Her vital signs are: BP 118/76 mmHg, HR 82 bpm, RR 16/min, Temp 98.4°F, SpO2 99%
on room air. She appears well-nourished and in no acute distress. Which
epidemiological factor most significantly increases her risk for an adverse pregnancy
outcome?
A. Advanced maternal age (≥35 years) [CORRECT]
B. Nulliparity
C. Regular menstrual cycles
D. Normal BMI
Correct Answer: A
Rationale: Advanced maternal age (≥35 years) is a well-established risk factor for
chromosomal abnormalities (e.g., Down syndrome), gestational diabetes, preeclampsia,
and other adverse pregnancy outcomes. Nulliparity is a risk factor but less significant
than advanced age. Regular cycles and normal BMI are actually protective factors, not
risks. (ACOG Practice Bulletin: Prenatal Diagnostic Testing for Genetic Disorders, 2016)
Q2: The patient is a G2P1 with one prior uncomplicated vaginal delivery at age 32. She
reports no history of miscarriage, ectopic pregnancy, or infertility. Her current
medications include a prenatal vitamin started 2 months ago and occasional ibuprofen
for headaches. Which piece of historical information is most critical to obtain next
regarding her obstetric history?
A. Details of her prior delivery including gestational age, birth weight, and any
complications [CORRECT]
,B. The brand of prenatal vitamin she is taking
C. Her exact date of last menstrual period
D. Frequency of ibuprofen use in the past month
Correct Answer: A
Rationale: A detailed obstetric history including prior delivery outcomes, gestational age,
birth weight, mode of delivery, and complications (e.g., gestational diabetes,
preeclampsia, preterm birth) directly informs risk stratification and prenatal care
planning for the current pregnancy. While LMP is important for dating, prior pregnancy
outcomes guide anticipatory guidance and screening. Ibuprofen use should be
addressed but is less critical than obstetric history. (USPSTF: Prenatal Care Guidelines)
Q3: The patient reports her last menstrual period (LMP) was 6 weeks ago. She has been
sexually active with her husband and uses no contraception. She reports breast
tenderness, mild nausea without vomiting, and increased urinary frequency over the
past 2 weeks. Based on these presenting symptoms, what is the most appropriate initial
diagnostic step?
A. Urine beta-hCG testing [CORRECT]
B. Serum quantitative beta-hCG
C. Transvaginal ultrasound
D. Complete blood count
Correct Answer: A
Rationale: Urine beta-hCG testing is the appropriate initial screening test for pregnancy
confirmation in a primary care setting. It is rapid, inexpensive, and highly sensitive.
Serum quantitative beta-hCG is reserved for suspected ectopic pregnancy or monitoring
trends. Transvaginal ultrasound is indicated after pregnancy is confirmed and hCG
levels reach discriminatory zone (~1,500-2,000 mIU/mL). CBC is not indicated at this
stage. (ACOG: Early Pregnancy Loss)
Q4: The patient's urine beta-hCG is positive. She asks about the reliability of home
pregnancy tests versus clinic-based testing. Which statement best explains the clinical
reasoning behind confirming pregnancy with a clinic-based test?
, A. Clinic-based tests use the same monoclonal antibody technology but provide
documentation and may detect lower hCG thresholds [CORRECT]
B. Home pregnancy tests are always less accurate than clinic tests
C. Clinic tests use completely different biochemical principles
D. Home tests are only reliable after 12 weeks gestation
Correct Answer: A
Rationale: Both home and clinic urine pregnancy tests detect beta-hCG using
monoclonal antibody immunoassay technology. Clinic-based tests may have lower
detection thresholds and provide documented results for the medical record, but
accuracy is similar when used correctly. Home tests are reliable as early as the first
missed period. The key difference is documentation and clinical correlation, not
fundamentally different technology. (ACOG: Home Use Tests)
Q5: The patient expresses concern because she is 35 years old and has heard about
increased risks. She asks what specific screening tests are recommended for women of
advanced maternal age. Which response best reflects evidence-based prenatal
screening guidelines?
A. Cell-free DNA testing, detailed anatomy ultrasound, and consideration of diagnostic
testing such as amniocentesis or CVS [CORRECT]
B. Only amniocentesis is recommended for all women over 35
C. No additional screening is needed beyond standard prenatal care
D. Triple screen is the gold standard for women over 35
Correct Answer: A
Rationale: For women ≥35 years, cell-free DNA (cfDNA) testing is recommended as a
first-tier screening option for aneuploidy. A detailed anatomy ultrasound at 18-22 weeks
is standard. Diagnostic testing (amniocentesis or CVS) should be offered and
discussed, particularly if screening is positive or there are additional risk factors.
Amniocentesis is not automatic for all women over 35. The triple/quad screen has been
largely replaced by cfDNA for high-risk populations. (ACOG Practice Bulletin No. 226:
Screening for Fetal Chromosomal Abnormalities)
